837
Views
18
CrossRef citations to date
0
Altmetric
Original Article

The economic cost of treatment-resistant depression in patients referred to a specialist service

, , , , , , , & show all
Pages 567-573 | Received 13 May 2017, Accepted 03 Nov 2017, Published online: 23 Dec 2017

References

  • Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. (2003). The epidemiology of major depressive episodes: Results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Method Psychiat Res, 12, 3–21
  • Andrews G. (2001). Should depression be managed as a chronic disease? BMJ, 322, 419–21
  • Beck AT, Steer RA, Brown G. (1996). Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation
  • Beecham J, Knapp M. (2001). Costing psychiatric interventions. In: G. Thornicroft, ed. Measuring mental health needs. London: Gaskell, 200–24
  • Berlim MT, Turecki G. (2007). What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Europ Neuropsychopharmacol, 17, 696–707
  • Broadhead WE, Blazer DG, George LK, Tse CK. (1990). Depression, disability days, and days lost from work in a prospective epidemiologic survey. J Am Med Assoc, 264, 2524–8
  • Bromet E, Andrade LH, Hwang I, et al. (2011). Cross-national epidemiology of DSM-IV major depressive episode. BMC Med, 9, 90
  • Calsyn RJ, Allen G, Morse GA, et al. (1993). Can you trust self-report data provided by homeless mentally ill individuals? Eval Rev, 17, 353–66
  • Choi S, Lee S, Matejkowski J, Baek YM. (2014). The relationships among depression, physical health conditions and healthcare expenditures for younger and older Americans. J Ment Health, 23, 140–5
  • Crown WH, Finkelstein S, Berndt ER, et al. (2002). The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry, 63, 963–71
  • Curran C, Knapp M, McDaid D, Tómasson K, The Mheen Group. (2007). Mental health and employment: An overview of patterns and policies across Western Europe. J Ment Health, 16, 195–209
  • Curtis L. (2011). Unit costs of health and social care. Canterbury: PSSRU
  • Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. (2004). Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. J Am Med Assoc, 291, 2581–90
  • Department of Health. (2011). National Schedule of Reference Costs 2009-10. London
  • Dimsdale JE, Jeste DV, Patterson TL. (2010). Beyond the global assessment of functioning: Learning from Virginia Apgar. Psychosomatics, 51, 515–9
  • First MB, Gibbon M, Spitzer RL, Williams JB. (2001). User's guide for the structured clinical interview for DSM-IV-TR Axis I disorders – Research version. New York: Biometric Research, New York State Psychiatric Institute
  • Fonagy P, Rost F, Carlyle JA, et al. (2015). Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression: The Tavistock Adult Depression Study (TADS). World Psychiatr, 14, 312–21
  • Fostick L, Silberman A, Beckman M, et al. (2010). The economic impact of depression: Resistance or severity? Eur Neuropsychopharmacol, 20, 671–5
  • Goldberg RW, Seybolt DC, Lehman A. (2002). Reliable self-report of health service use by individuals with serious mental illness. Psychiatr Serv, 53, 879–81
  • Greden JF. (2001). The burden of disease for treatment-resistant depression. J Clin Psychiatr, 62, 26–31
  • Hamilton M. (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol, 6, 278–96
  • Hilsenroth MJ, Ackerman SJ, Blagys MD, et al. (2000). Reliability and validity of DSM-IV axis V. Am J Psychiatry, 157, 1858–63
  • Hollinghurst S, Carroll FE, Abel A, et al. (2014). Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: Economic evaluation of the CoBalT Trial. Br J Psychiatr, 204, 69–76
  • Ivanova JI, Birnbaum HG, Kidolezi Y, et al. (2010). Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr Med Res Opin, 26, 2475–84
  • Kessler RC, Berglund P, Demler O, et al. (2003). The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289, 3095–105
  • Kessler RC, Frank RG. (1997). The impact of psychiatric disorders on work loss days. Psychol Med, 27, 861–73
  • Kubitz N, Mehra M, Potluri RC, et al. (2013). Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLos One, 8, e76882
  • McCrone P, Dhanasiri S, Patel A, et al. (2008). Paying the price. The cost of mental health care in England in 2026. London: King's Fund
  • McManus S, Meltzer H, Brugha T, et al. (2009). Adult psychiatric morbidity in England, 2007: Results of a household survey. London: National Health Service Information Centre for Health and Social Care
  • Mihaylova B, Briggs A, O’Hagan A, Thompson SG, et al. (2011). Review of statistical methods for analysing healthcare resources and costs. Health Econ, 20, 897–916
  • Mrazek DA, Hornberger JC, Altar CA, Degtiar I. (2014). A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr Serv, 65, 977–87
  • Office for National Statistics. (2011). Annual Survey of Hours and Earnings, 2010 Revised Results. Available from: http://webarchive.nationalarchives.gov.uk/20151013205951/http://www.ons.gov.uk/ons/rel/ashe/annual-survey-of-hours-and-earnings/2010-revised-results/index.html [last accessed 23 October 2017]
  • Olchanski N, McInnis Myers M, Halseth M, et al. (2013). The economic burden of treatment-resistant depression. Clin Therap, 35, 512–22
  • Richards D. (2011). Prevalence and clinical course of depression: A review. Clin Psychol Rev, 31, 1117–25
  • Simon GE, Goldberg DP, Von Korff M, Ustun TB. (2002). Understanding cross-national differences in depression prevalence. Psychol Med, 32, 585–94
  • Smith GN, Ehmann TS, Flynn SW, et al. (2011). The assessment of symptom severity and functional impairment with DSM-IV axis V. Psychiatr Serv, 62, 411–17
  • Stegmann ME, Ormel J, de Graaf R, et al. (2010). Functional disability as an explanation of the associations between chronic physical conditions and 12-month major depressive episode. J Affect Disord, 124, 38–44
  • Stimpson N, Agrawal N, Lewis G. (2002). Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression. Systematic review. Br J Psychiatr, 181, 284–94
  • Taylor D, Carlyle JA, McPherson S, et al. (2012). Tavistock Adult Depression Study (TADS): A randomised controlled trial of psychoanalytic psychotherapy for treatment-resistant/treatment-refractory forms of depression. BMC Psychiatry, 12, 60
  • Thomas L, Kessler D, Campbell J, et al. (2013). Prevalence of treatment-resistant depression in primary care: Cross-sectional data. Br J Gen Pract, 63, e852. 858
  • WHO. (2010). Depression. Available from: http://www.who.int/mental_health/management/depression/definition/en/ [last accessed 27 July 2016]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.